早期高危、淋巴结阴性子宫内膜癌患者术后辅助铂类化疗和阴道近距离放疗的失败模式和临床结局。
Patterns of Failures and Clinical Outcome of Patients with Early-Stage, High-Risk, Node-Negative Endometrial Cancer Treated with Surgery Followed by Adjuvant Platinum-Based Chemotherapy and Vaginal Brachytherapy.
机构信息
Department of New Technologies and Translational Research, Division of Radiation Oncology, University of Pisa, Pisa, Italy,
Department of Experimental and Clinical Medicine, Division of Gynecology and Obstetrics, University of Pisa, Pisa, Italy.
出版信息
Oncology. 2019;96(5):235-241. doi: 10.1159/000492430. Epub 2019 Mar 22.
OBJECTIVE
To assess the clinical outcome of patients with high-risk early-stage endometrial cancer and negative pelvic nodes who received adjuvant platinum-based chemotherapy plus vaginal brachytherapy (VBT).
METHODS
This investigation assessed 80 patients who underwent hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymphadenectomy for stage Ib-II, grade 2-3 endometrioid (n = 43) or stage Ia-II nonendometrioid (n = 37) endometrial cancer.
RESULTS
Five-year local control rate, 5-year disease-free survival, and 5-year overall survival were 97, 87, and 97%, respectively, for endometrioid carcinoma, and 66, 50, and 72%, respectively, for nonendometrioid carcinoma.
CONCLUSIONS
This retrospective study appears to show that adjuvant platinum-based chemotherapy plus VBT achieve very good results in endometrioid carcinoma. This combined treatment seems to be less effective in nonendometrioid carcinoma.
目的
评估接受辅助铂类化疗联合阴道近距离放疗（VBT）的高危早期子宫内膜癌且盆腔淋巴结阴性患者的临床结局。
方法
本研究评估了 80 例接受子宫切除术、双侧输卵管卵巢切除术和盆腔淋巴结切除术的患者，这些患者患有 Ib-II 期、组织学分级 2-3 级子宫内膜样（n=43）或 Ia-II 期非子宫内膜样（n=37）子宫内膜癌。
结果
对于子宫内膜样癌，5 年局部控制率、5 年无病生存率和 5 年总生存率分别为 97%、87%和 97%，而非子宫内膜样癌则分别为 66%、50%和 72%。
结论
这项回顾性研究似乎表明，辅助铂类化疗联合 VBT 可使子宫内膜样癌获得非常好的结果。这种联合治疗在非子宫内膜样癌中的效果似乎较差。
Zotero 插件